Merck Announces KEYLYNK-008 Trial Evaluating KEYTRUDA (pembrolizumab) Plus LYNPARZA (olaparib) for Patients With Metastatic Squamous Non-Small Cell Lung Cancer to Stop for Futility

07.12.2023 - Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that it will stop the Phase 3 KEYLYNK-008 trial evaluating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with maintenance LYNPARZA, a PARP inhibitor, for ...

Related Keywords

United States ,Canada , ,Linkedin ,Astrazeneca ,Twitter ,Instagram ,Merck Research Laboratories ,Merck Co Stock ,Youtube ,Statement Of Merck Co Inc ,Exchange Commission ,Merck Co Inc ,Facebook ,Merck Research ,Response Evaluation Criteria ,Solid Tumors ,Induction Phase ,Maintenance Phase ,Selected Important Safety ,Important Safety Information ,Fatal Immune Mediated Adverse ,Which Can Present With Diabetic ,Nervous System ,Patients With Multiple ,Neck Squamous Cell ,Mismatch Repair Deficient ,Mismatch Repair Deficient Colorectal ,Prescribing Information ,Medication Guide ,Acute Myeloid Leukemia ,Fetal Toxicity ,First Line Maintenance ,Advanced Ovarian ,First Line Maintenance Advanced Ovarian Cancer ,Recurrent Ovarian ,Adjuvant Treatment ,High Risk Early Breast ,Negative Metastatic Breast ,Metastatic Pancreatic ,Metastatic Castration Resistant Prostate ,Metastatic Castration Resistant Prostate Cancer ,Positive Advanced Ovarian Cancer ,Line Maintenance ,Looking Statement ,Litigation Reform Act ,Annual Report ,Merck Co Chart ,Erck Co Kurs ,Erck Co Aktie ,